Compare · Head-to-head
KPV vs Melanotan I.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Melanotan I, then use the table to confirm fit.
Melanotan I is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01 · At a glance
| Decision factor | KPV | Melanotan I |
|---|---|---|
| Primary fit | tissue repair & recovery and immune support comparisons | skin & hair research where you want a clear starting point |
| Evidence | Tier C | Tier A |
| Risk | med-high | medium |
| Experience level | intermediate | advanced |
| Budget tier | mid | premium |
| Administration route | topical, subcutaneous | subcutaneous implant |
02 · Use case & timing
| Decision factor | KPV | Melanotan I |
|---|---|---|
| Goal fit | Tissue Repair & Recovery, Immune Support, Skin & Hair | Skin & Hair |
| What users compare it for | Preclinical anti-inflammatory effects; skin/gut inflammation research. | Phototoxicity reduction in EPP (evidence-backed). Cosmetic tanning is not the approved use. |
| Onset timeline | Cell signaling endpoints are acute; clinical translation unknown. | Controlled-release kinetics; plasma concentrations up to ~96 hours in most subjects. |
| Main tradeoff | Evidence and product availability can still be uneven, so documentation matters more than hype. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | KPV | Melanotan I |
|---|---|---|
| Adverse effects | Limited direct human data. | Hypersensitivity, implant site reactions, pigment changes, monitoring for pigmented lesions. |
| Contraindications | No data. | Hypersensitivity to afamelanotide (per label). |
| Interaction notes | Unknown. | No drug interaction studies were conducted (per label). |
| Regulatory status | Not approved | Prescription-approved |
| FDA flag | FDA status unclear | No current flag noted |
| WADA status | Not listed | Status unclear |
04 · Age & monitoring
| Decision factor | KPV | Melanotan I |
|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | KPV | Melanotan I |
|---|---|---|
| Typical cycle cost | $31.99 | No reliable estimate yet |
| Estimated monthly cost | $42.66 | No reliable estimate yet |
| Cost confidence | High confidence | No estimate |
06 · Before you buy
| Decision factor | KPV | Melanotan I |
|---|---|---|
| Tracked vendor listings | 3 listings | 2 listings |
| Sourcing note | Product format varies by listing, so double-check route, concentration, and presentation. | Tracked product pages are available, which makes it easier to review the listing before you click out. |
| Stack-friendly? | Usually stack-friendly | Better as a standalone decision |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.